Abstract:Sarcopenia, a disease recognized by the World Health Organization, has posed a great challenge to the world in the current aging society. The vital role of the gut microbiome through the gut-muscle axis in sarcopenia is increasingly recognized. However, the working mechanisms by which the gut microbiota functions have not been fully explored in the multi-omics field. Here, we designed a cross-sectional study that recruited patients ( n = 32) with sarcopenia and healthy old adults ( n = 31). Diagnosis of sarcopenia was based on the Asian Working Group for Sarcopenia (AWGS) in 2019 criteria. Muscle mass was represented by appendicular skeletal muscle mass measured by using direct segmental multi-frequency bioelectrical impedance and muscle strength was evaluated using the handgrip strength. The Short Physical Performance Battery, the 5-time Chair Stand Test, and the 4-metre Walk Test were used to assess physical performance. Shotgun metagenomic sequencing was used to profile the gut microbiome in order to identify its construction and function. Metabolome based on untargeted metabolomics was applied to describe the features and structure of fecal metabolites. In clinical indexes including triglycerides and high-density lipoprotein cholesterol, we noted a significant decrease in triglycerides (TG) and a significant increase in high-density lipoprotein cholesterol (HDL-C) in patients with sarcopenia. Appendicular skeletal muscle mass of patients with sarcopenia was lower than the health group. Based on intestinal metagenomic and fecal metabolomic profiles, we found that the gut microbiome and metabolome were disturbed in patients with sarcopenia, with significant decreases in bacteria such as Bifidobacterium longum , Bifidobacterium pseudocatenulatum , and Bifidobacterium adolescentis , as well as metabolites such as shikimic acid. Also, we plotted supervised classification models at the species level of gut bacteria (AUC = 70.83–88.33) and metabolites (AUC = 92.23–98.33) based on machine learning, respectively. Based on the gut-muscle axis network, a potential mechanism is proposed along the gut microbiome - key metabolites - clinical index, that Phascolarctobacterium faecium affects appendicular skeletal muscle mass, calf circumference, handgrip strength, and BMI via Shikimic acid metabolites. This study elucidates the potential mechanisms by which the gut microbiome influences the progress of sarcopenia through metabolites and provides a meaningful theoretical foundation for reference in the diagnosis and treatment of sarcopenia.

Reduced energy metabolism contributing to aging of skeletal muscle by serum metabolomics and gut microbiota analysis

Integrated Multi-Omics Analysis Identifies Disrupted Branched-Chain Amino Acid Catabolism As Causal for Sarcopenia

The Effect of Metabolites on Mitochondrial Functions in the Pathogenesis of Skeletal Muscle Aging

Metabolites of the gut microbiota may serve as precise diagnostic markers for sarcopenia in the elderly

Characteristics of the gut microbiome and metabolic profile in elderly patients with sarcopenia

Metabolic analysis of sarcopenic muscle identifies positive modulators of longevity and health span in C. elegans

Mitochondrial pathways and sarcopenia in the geroscience era

Post‐translational regulation of muscle growth, muscle aging and sarcopenia

Characterization of the Skeletal Muscle Proteome in Undernourished Old Rats

High-throughput sequencing analysis of the characteristics of the gut microbiota in aged patients with sarcopenia

Aging and sarcopenia associate with specific interactions between gut microbes, serum biomarkers and host physiology in rats

Mechanisms Linking the Gut-Muscle Axis With Muscle Protein Metabolism and Anabolic Resistance: Implications for Older Adults at Risk of Sarcopenia

Sarcopenia: Molecular regulatory network for loss of muscle mass and function

Cross-Species Studies Reveal That Dysregulated Mitochondrial Gene Expression and Electron Transport Complex I Activity Are Crucial for Sarcopenia

Mitochondrial Quantity and Quality in Age-Related Sarcopenia

Autophagy As a Potential Target for Sarcopenia

Metabolic signatures and risk of sarcopenia in suburb-dwelling older individuals by LC-MS–based untargeted metabonomics

The Combination of Lactoferrin and Creatine Ameliorates Muscle Decay in a Sarcopenia Murine Model

Mitochondrial involvement in sarcopenia

Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials

Novel metabolic and lipidomic biomarkers of sarcopenia